| Region: | |
| Category: |
(14 reports matching your criteria)
|
MediPoint: Total Wrist Reconstruction - US Analysis and Market Forecasts
3/31/2013 | published by: GlobalData
... condition for patients considering a total wrist replacement surgery. Two major categories of arthritis may affect the wrist joint, namely osteoarthritis and rheumatoid or inflammatory arthritis. Post traumatic arthritis is another reason for the onset ...
|
read more...
|
$4,450.00
|
|
PharmaPoint: Rheumatoid Arthritis - United States Drug Forecast and Market Analysis Event-Driven Update
11/30/2012 | published by: GlobalData
... RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer’s Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly’s anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ’s ...
|
read more...
|
$4,995.00
|
|
TreatmentTrends®: Rheumatoid Arthritis US (Wave 3) 2012
9/26/2012 | published by: Decision Resources
... patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. TreatmentTrends® are syndicated report series that provide longitudinal information ...
|
read more...
|
$15,000.00
|
|
ChartTrends®: Rheumatoid Arthritis (US) 2012
9/11/2012 | published by: Decision Resources
... what physicians self-report about disease management to what actually occurs at the patient level. Through an in-depth review of specific patient charts, details such as product dosing and titration, switching, concomitant medications, and a host ...
|
read more...
|
$15,000.00
|
|
The United States Rheumatic Diseases Therapeutics Market
8/28/2012 | published by: Frost & Sullivan
... prescribed as add-on therapies for rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS); background standard of care therapies are not covered in this study. Included in the study are products already on the ...
|
read more...
|
$9,500.00
|
|
PatientTrends®: Rheumatoid Arthritis (US) 2012
8/17/2012 | published by: Decision Resources
... satisfaction with their physician and their thera-peutic regimen. This report will also examine how patients seek out information about their disease and what product attributes would encour-age patients to seek a switch in therapies, particularly ...
|
read more...
|
$10,000.00
|
|
United States Market for Rheumatoid Arthritis Pharmacotherapeutics
7/5/2012 | published by: Frost & Sullivan
... standard of care. Included in the study are products of the market and products in development, as well as patient and revenue forecasts. Market challenges, drivers, and restraints are identified and assessed. Treatment paradigms for ...
|
read more...
|
$6,000.00
|
|
TreatmentTrends®: Rheumatoid Arthritis (Wave 2) US 2012
6/29/2012 | published by: Decision Resources
... patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. TreatmentTrends® are syndicated report series that provide longitudinal information ...
|
read more...
|
$15,000.00
|
|
TreatmentTrends®: Rheumatoid Arthritis (Wave 1) US 2012
3/26/2012 | published by: Decision Resources
... patient market share, perceived strengths and weaknesses of the key brands, barriers to broader usage, sales force performance and perceived value of manufacturers’ patient assistance programs. TreatmentTrends® are syndicated report series that provide longitudinal information ...
|
read more...
|
$15,000.00
|
|
LaunchTrends®: Krystexxa (US)(Wave 4) 2012
3/15/2012 | published by: Decision Resources
... syndicated reports that track the trial, adoption and usage of new products at one month, three months, six months, and 12 months post launch. These report series provide information on how new products fit into ...
|
read more...
|
$15,000.00
|
|
U.S. Rheumatoid Arthritis Market: Assessment of Biologics and New Treatments
5/2/2011 | published by: Frost & Sullivan
... patient forecasts. Market challenges, drivers, and restraints are identified and assessed. Strategic recommendations are presented to overcome listed industry challenges. This research service does not include market revenue forecasts for DMARDs. This research service highlights ...
|
read more...
|
$6,000.00
|
|
Arthritis - US
2/1/2011 | published by: Mintel International Group Ltd.
... Oral and topical analgesics that are specially formulated for the treatment of arthritis pain and marketed to this demographic may meet with success, especially in light of Tylenol’s product recalls (Tylenol’s Arthritis Pain dominates the ...
|
read more...
|
$3,995.00
|
|
US Markets for Large-Joint Reconstructive Implants 2010
4/23/2010 | published by: Millennium Research Group
... procedure growth and market revenues will continue to ascend. Dampened procedural growth led to slowed unit sales from 2008 to 2009 because the economic crisis forced some patients to delay surgery until after the recession. ...
|
read more...
|
$4,337.00
|
|
Psoriasis and Psoriatic Arthritis: A Strategic Analysis of the Market in the United States
9/1/2006 | published by: Kalorama Information
... market effects of new therapeutics, with the potential of a breakthrough drug always a possibility, are expected to be seen over the next ten years. The technology trends selected in conjunction with the growing interest ...
|
read more...
|
$1,500.00
|